Takeda emphasizes strategy for delivering sustainable growth over next decade at the 40th annual j.p. morgan healthcare conference

Osaka, japan & cambridge, mass.--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today confirmed the company is positioned for growth in the mid- and long-term with the potential to deliver incremental revenue growth and additional upside potential through fy2030. presenting at the 40th annual j.p. morgan healthcare conference, christophe weber, takeda's president and chief executive officer, reinforced the mid-term revenue growth potential of its 14 global
TAK Ratings Summary
TAK Quant Ranking